What drugs are in PharmaEssentia’s pipeline besides BESREMi?
PharmaEssentia’s published early-stage pipeline lists anti-PD-1 P1801 for solid tumors and PEG-GCSF P2203 for neutropenia. [1]
The same pipeline also lists TCR-T for solid tumors and PEG-cytokines, including IL-2, for solid tumors and immunology. [1]
Other listed programs include novel checkpoint antibodies for solid and hematologic tumors, a bispecific immunocytokine for solid tumors, and P1101 plus anti-PD-1 for HCC. [1]
Dated evidence
| Claim | Value | As of | Source and original quotation |
|---|---|---|---|
| Anti-PD-1 candidate | P1801; solid tumors | 2026-10-22 | Primary sourceanti PD-1 (P1801) |
| PEG-GCSF candidate | P2203; neutropenia | 2026-10-22 | Primary sourcePEG-GCSF (P2203) |
| Cell therapy candidate | TCR-T; solid tumors | 2026-10-22 | Primary sourceTCR-T |
| Cytokine candidates | PEG-cytokines, including IL-2; solid tumors and immunology | 2026-10-22 | Primary sourcePEG-cytokines (e.g., IL-2) |
| Checkpoint antibodies | Novel checkpoint antibodies; solid and hematologic tumors | 2026-10-22 | Primary sourceNovel checkpoint Abs |
| Bispecific immunocytokine | Solid tumors | 2026-10-22 | Primary sourceImmunocytokine |
| Combination program | P1101 plus anti-PD-1; HCC | 2026-10-22 | Primary sourceP1101 |
Not disclosed in the public documents
The checked public pipeline does not provide an exact next readout or approval date for these early-stage programs. Document reviewed 2026-10-22
Robust Early-Stage Pipeline